Oncotype DX
A genomic test that analyzes the expression of 21 genes to predict recurrence risk and chemotherapy benefit in early-stage breast cancer.
Full Definition
Oncotype DX is a commercially available multigene assay primarily used in hormone receptor-positive, HER2-negative breast cancer to guide treatment decisions. The test measures the expression levels of 16 cancer-related genes and 5 reference genes to generate a Recurrence Score ranging from 0 to 100. This score helps oncologists determine whether a patient would benefit from adjuvant chemotherapy in addition to hormonal therapy. The test has been validated in multiple clinical trials and is considered standard of care for appropriate candidates, significantly impacting treatment recommendations and reducing unnecessary chemotherapy exposure.
Usage
Usage note: Trademark should be capitalized; often followed by registered trademark symbol in formal documents.
In Context
- "The Oncotype DX score of 12 indicated low recurrence risk, supporting the decision to forgo adjuvant chemotherapy." — Clinical decision note
- "Insurance coverage for Oncotype DX testing varies by provider, requiring prior authorization documentation." — Administrative guideline